17 research outputs found
Additional file 1: of Financial transfers from adult children and depressive symptoms among mid-aged and elderly residents in China - evidence from the China health and retirement longitudinal study
CESD-10 questions and answers (DOCX 15 kb
Direct costs used for lymphatic filariasis with lower and upper limits [between brackets].
<p>Direct costs used for lymphatic filariasis with lower and upper limits [between brackets].</p
Global economic benefit (productivity loss prevented) for the period 2011–2030 (billions I$—international dollars)
<p>Global economic benefit from reaching the targets for 5 PCT diseases, lower and upper estimates from sensitivity analysis.</p
Global economic benefit or reaching the targets for STH (point estimates), per disease sequela for the period 2011–2030 (billions I$—international dollars)
<p>STH is the disease responsible for the largest economic impact, especially the anemia sequela. The 2.5 and 97.5 percentiles calculated in the sensitivity analysis are shown in the diagram.</p
Productivity loss due to skin disease from onchocerciasis according to the counterfactual and target achievement scenarios (millions I$—international dollars)
<p>Total global loss per year in the counterfactual scenario (blue) and target achievement scenario (orange). The economic benefit is the difference between both scenarios.</p
Lower and upper limits used in the sensitivity analyses.
<p>Lower and upper limits used in the sensitivity analyses.</p
Productivity loss due to Chagas chronic heart disease according to the counterfactual and target achievement scenarios (millions I$—International dollars).
<p>Total global loss per year in the counterfactual scenario (blue) and target achievement scenario (orange). The economic benefit is the difference between both scenarios.</p
Global economic benefit (productivity loss averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars).
<p>Global economic benefit from reaching the targets for IDM NTDs, lower and upper estimates from sensitivity analysis. Global economic benefit per disease.</p
Global economic benefit (out-of-pocket payments averted) for IDM NTDs, for the period 2011–2030 (billions I$—International dollars).
<p>Total economic benefit from out-of-pocket payments averted, base case estimates and 2.5th and 97.5th percentiles (billions I$—international dollars), discounting 3% from 2010.</p
Out-of-pocket payments, percentage of patients being treated and percentage of patients paying for treatment according to the literature, used in the calculations for Chagas disease (I$—International dollars).
<p>Out-of-pocket payments, percentage of patients being treated and percentage of patients paying for treatment according to the literature, used in the calculations for Chagas disease (I$—International dollars).</p